|
1
|
Bussom S and Saif MW: Methods and
rationale for the early detection of pancreatic cancer. Highlights
from the '2010 ASCO Gastrointestinal Cancers Symposium' Orlando,
FL, USA. January 22-24, 2010. JOP. 11:128–130. 2010.PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niedergethmann M, Alves F, Neff JK,
Heidrich B, Aramin N, Li L, Pilarsky C, Grützmann R, Allgayer H,
Post S and Gretz N: Gene expression profiling of liver metastases
and tumour invasion in pancreatic cancer using an orthotopic SCID
mouse model. Br J Cancer. 97:1432–1440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu H, Zhao J and Lv J: Inhibitory effects
of miR-101 overex-pression on cervical cancer SiHa cells. Eur J
Gynaecol Oncol. 38:236–240. 2017.
|
|
6
|
Kasinski AL and Slack FJ: Epigenetics and
genetics MicroRNAs en route to the clinic: Progress in validating
and targeting microRNAs for cancer therapy. Nat Rev Cancer.
11:849–864. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Li H, Zhang R and Liu J and Liu J:
MicroRNA-449a inhibits proliferation and induces apoptosis by
directly repressing E2F3 in gastric cancer. Cell Physiol Biochem.
35:2033–2042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang C, Ning S, Li Z, Qin X and Xu W:
miR-22 is down-regulated in esophageal squamous cell carcinoma and
inhibits cell migration and invasion. Cancer Cell Int. 14:1382014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Liu CG, Sevignani C, Ferracin M,
Felli N, Dumitru CD, Shimizu M, Cimmino A, Zupo S, Dono M, et al:
MicroRNA profiling reveals distinct signatures in B cell chronic
lymphocytic leukemias. Proc Natl Acad Sci USA. 101:11755–11760.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ming J, Zhou Y, Du J, Fan S, Pan B, Wang
Y, Fan L and Jiang J: miR-381suppresses C/EBPα-dependent Cx43
expression in breast cancer cells. Biosci Rep. 35:2015. View Article : Google Scholar
|
|
12
|
Xia B, Li H, Yang S, Liu T and Lou G:
MiR-381 inhibits epithelial ovarian cancer malignancy via YY1
suppression. Tumour Biol. 37:9157–9167. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Zhao C, Yu Z, Chen J, She X, Li P,
Liu C, Zhang Y, Feng J, Fu H, et al: Low expression of miR-381 is a
favorite prognosis factor and enhances the chemosensitivity of
osteosarcoma. Oncotarget. 7:68585–68596. 2016.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
15
|
Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot
CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, et al: Integrated
analyses identify a master microRNA regulatory network for the
mesenchymal subtype in serous ovarian cancer. Cancer Cell.
23:186–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Urruticoechea A, Smith IE and Dowsett M:
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol.
23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang Y, Yan W, He X, Zhang L, Li C, Huang
H, Nace G, Geller DA, Lin J and Tsung A: miR-375 inhibits autophagy
and reduces viability of hepatocellular carcinoma cells under
hypoxic conditions. Gastroenterology. 143:177–187.e8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang P, Zhang J, Zhang L, Zhu Z, Fan J,
Chen L, Zhuang L, Luo J, Chen H, Liu L, et al: MicroRNA 23b
regulates autophagy associated with radioresistance of pancreatic
cancer cells. Gastroenterology. 145:1133–1143.e12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Du Q, Park KS, Guo Z, He P, Nagashima M,
Shao L, Sahai R, Geller DA and Hussain SP: Regulation of human
nitric oxide synthase 2 expression by Wnt beta-catenin signaling.
Cancer Res. 66:7024–7031. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Osada H and Takahashi T: MicroRNAs in
biological processes and carcinogenesis. Carcinogenesis. 28:2–12.
2007. View Article : Google Scholar
|
|
22
|
Zhang X, Li D, Li M, Ye M, Ding L, Cai H,
Fu D and Lv Z: MicroRNA-146a targets PRKCE to modulate papillary
thyroid tumor development. Int J Cancer. 134:257–267. 2014.
View Article : Google Scholar
|
|
23
|
Munker R and Calin GA: MicroRNAs and other
non-coding RNAs: Implications for cancer patients. MicroRNA Cancer.
1–12. 2013.
|
|
24
|
Zhang C, Wang C, Chen X, Yang C, Li K,
Wang J, Dai J, Hu Z, Zhou X, Chen L, et al: Expression profile of
MicroRNAs in Serum: A fingerprint for esophageal squamous cell
carcinoma. Clin Chem. 56:1871–1879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang RS, Zheng YL, Zhao J and Chun X:
microRNA-381 suppresses the growth and increases cisplatin
sensitivity in non-small cell lung cancer cells through inhibition
of nuclear factor-κB signaling. Biomed Pharmacother. 98:538–544.
2018. View Article : Google Scholar
|
|
26
|
Zhang M, Huang S and Long D: MiR-381
inhibits migration and invasion in human gastric carcinoma through
downregulatedting SOX4. Oncol Lett. 14:3760–3766. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Ruan H, Hu X, Cao A and Song L:
miR-381-3p suppresses the proliferation of oral squamous cell
carcinoma cells by directly targeting FGFR2. Am J Cancer Res.
7:913–922. 2017.PubMed/NCBI
|
|
28
|
Xue Y, Xu W, Zhao W, Wang W, Zhang D and
Wu P: miR-381 inhibited breast cancer cells proliferation,
epithelial-to-mesen-chymal transition and metastasis by targeting
CXCR4. Biomed Pharmacother. 86:426–433. 2017. View Article : Google Scholar
|
|
29
|
Zhang Q, Zhao S, Pang X and Chi B:
MicroRNA-381 suppresses cell growth and invasion by targeting the
liver receptor homolog-1 in hepatocellular carcinoma. Oncol Rep.
35:1831–1840. 2016. View Article : Google Scholar
|
|
30
|
Liao H, Pan Y, Pan Y, Shen J, Qi Q, Zhong
L, Han W, Wang Q and Jiang Y: MicroRNA-874 is downregulated in
cervical cancer and inhibits cancer progression by directly
targeting ETS1. Oncol Rep. 40:2389–2398. 2018.PubMed/NCBI
|
|
31
|
Buggy Y, Maguire TM, McGreal G, McDermott
E, Hill AD, O'Higgins N and Duffy MJ: Overexpression of the Ets-1
transcription factor in human breast cancer. Br J Cancer.
91:1308–1315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu Y, Zhang YC, Zhang WZ, Shen LS, Hertzog
P, Wilson TJ and Xu DK: Ets1 as a marker of malignant potential in
gastric carcinoma. World J Gastroenterol. 9:2154–2159. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki H, Romano-Spica V, Papas TS and
Bhat NK: ETS1 suppresses tumorigenicity of human colon cancer
cells. Proc Natl Acad Sci USA. 92:4442–4446. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 1995. View Article : Google Scholar
|
|
35
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toker A and Cantley LC: Signalling through
the lipid products of phosphoinositide-3-OH kinase. Nature.
387:673–676. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cantley LC and Neel BG: New insights into
tumor suppression: PTEN suppresses tumor formation by restraining
the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA.
96:4240–4245. 1999. View Article : Google Scholar : PubMed/NCBI
|
